Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Highlighting Ovarian Cancer Landscape and Lead Candidate ERNA-101
Rhea-AI Summary
Ernexa Therapeutics (Nasdaq: ERNA) released a Virtual Investor KOL Connect segment featuring Chief Scientific Officer Dr. Robert Pierce discussing ovarian cancer, treatment limitations, and the company’s approach.
The company will also join a Virtual Investor Closing Bell event on May 13, 2026, highlighting preclinical ERNA-101 ovarian cancer data showing complete tumor elimination and 100% survival in models when combined with PD-1 blockade.
Positive
- Preclinical ERNA-101 data showed complete tumor elimination in ovarian cancer models with PD-1 blockade
- Preclinical ERNA-101 data showed 100% survival in ovarian cancer models with PD-1 blockade
- Investor-facing KOL segment increases visibility of ERNA-101’s ovarian cancer strategy
Negative
- None.
News Market Reaction – ERNA
In the May 11 session, ERNA declined 4.25%, reflecting a moderate negative market reaction. Argus tracked a peak move of +124.4% during that session. Argus tracked a trough of -5.4% from its starting point during tracking. Our momentum scanner triggered 33 alerts that day, indicating elevated trading interest and price volatility. Trading volume was elevated at 2.2x the daily average, suggesting increased selling activity.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 06 | Preclinical data update | Positive | +51.4% | ERNA-101 plus PD-1 showed complete tumor clearance and 100% survival. |
| Apr 30 | Reverse stock split | Negative | -21.2% | 1-for-25 reverse split to regain Nasdaq minimum bid compliance. |
| Mar 31 | Pipeline and financing | Positive | +5.3% | Outlined ERNA-101 trial timing plus $10.5M financing and 61% G&A reduction. |
| Feb 20 | Investor event | Neutral | -17.3% | Announcement of participation in a Virtual Investor Closing Bell event. |
| Feb 06 | Dilutive offering | Negative | -44.7% | $10.5M best-efforts offering of stock and warrants at $0.50 per unit. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
News flow over the last six months shows ERNA reacts strongly to financing and structural actions (notably the public offering and reverse split) with sharp declines, while positive ERNA-101 preclinical updates have coincided with large gains. Neutral investor-relations events have sometimes seen negative price moves, indicating sentiment sensitivity beyond pure data releases.
Over recent months, Ernexa has combined balance-sheet repair with advancing ERNA-101. A $10.5M offering on Feb 6, 2026 and a 1-for-25 reverse split on Apr 30, 2026 prompted sharp declines. In contrast, ERNA-101 preclinical data on Mar 31 and especially May 6, 2026 drove gains of 5.29% and 51.38%. Today’s KOL-focused segment and discussion of ovarian cancer and ERNA-101 builds directly on that May 6 dataset and prior catalyst messaging.
Key Terms
kol technical
pd-1 blockade medical
tumor microenvironment medical
immunologically “cold” tumors medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Moderated discussion with Chief Scientific Officer Dr. Robert Pierce on ovarian cancer and evolving treatment landscape
Segment highlights significant unmet need in ovarian cancer and the potential of ERNA-101 to address limitations of current therapies
Access the segment here
Company to also participate in Virtual Investor Closing Bell event on May 13 featuring Sanjeev Luther and Dr. Robert Pierce
Register for the Closing Bell event here
CAMBRIDGE, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the release of a Virtual Investor KOL Connect segment featuring Dr. Robert Pierce, Chief Scientific Officer of Ernexa.
As part of the segment, Dr. Pierce provides insight into the complexities of ovarian cancer, one of the most challenging malignancies to treat, and discusses the limitations of current therapeutic approaches. The discussion highlights the patient journey from diagnosis through treatment, emphasizing the persistent unmet need for more effective and durable treatment options.
Dr. Pierce also outlines the evolving treatment landscape and shares his perspective on how Ernexa is approaching ovarian cancer differently at the biological level. He discusses the Company’s lead product candidate, ERNA-101, and its potential to improve outcomes and enhance the patient experience compared to existing therapies.
The Virtual Investor KOL Connect segment featuring Ernexa Therapeutics is now available here.
In addition, Ernexa announced that Sanjeev Luther, President & Chief Executive Officer, and Dr. Robert Pierce, Chief Scientific Officer, will participate in a Virtual Investor Closing Bell event on Wednesday, May 13, 2026, at 4:00 PM ET.
As part of the event, Mr. Luther and Dr. Pierce will provide a corporate overview and discuss Ernexa’s recently announced preclinical ovarian cancer data for ERNA-101, which demonstrated complete tumor elimination and
For more information about ERNA-101 and the Company’s development plans, visit www.ernexatx.com
About Ernexa Therapeutics
Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative cell therapies for the treatment of advanced cancer and autoimmune diseases. Ernexa’s core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa’s allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting.
ERNA-101 is the company’s lead cell therapy product, designed to activate and regulate the immune system's response to recognize and attack cancer cells. ERNA-201 is a cell therapy product designed to target inflammation and treat autoimmune disease. The company’s initial focus is to develop ERNA-101 for the treatment of ovarian cancer.
For more information, visit www.ernexatx.com.
Media Contact
Sharon Golubchik
RAYNZ
sharon@raynzhealth.com
Investor Contact
Jenene Thomas
JTC Team, LLC
(908) 824-0775
ERNA@jtcir.com
